Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 844 across all filing types
Latest filing 2012-02-05 AGM Information
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
Chairman`s Address to Shareholders - Gen Meeting 7 Feb 2012 5 pages 209.3KB
AGM Information Classification · 95% confidence The document is a Chairman's Address delivered at a General Meeting, dated 6 February 2012, discussing a proposed series of transactions including an off-market takeover bid, capital raising through a public offer, share consolidation, and board appointments. It includes detailed descriptions of the proposed transactions, expected benefits, suspension and re-admission to the ASX, and recommendations of directors on voting. The content is focused on corporate actions and shareholder meeting matters rather than financial results or detailed financial statements. It is not a full Annual Report, Interim Report, or Earnings Release. It is not a proxy solicitation or voting results announcement, but rather a speech or presentation at a general meeting. The document length (over 10,000 characters) and detailed content suggest it is not a brief announcement or regulatory filing. The nature of the document aligns best with materials shared during a general meeting, specifically the Chairman's Address, which fits the category AGM Information (AGM-R).
2012-02-05 English
Extension Of Public Offer Period 2 pages 54.6KB
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Probiomics Limited regarding the extension of the public offer period related to a prospectus dated 21 December 2011. It details amended dates for the closing of the public offer and other related events such as share issues, share consolidation, and a company name change. The document is short (2919 characters) and primarily communicates changes to the timetable of a capital raising event. There are no financial statements, detailed financial analysis, or management discussion of results. This is an update on financing activity, specifically about the public offer period extension, which fits the Capital/Financing Update category. It is not a full report, earnings release, or regulatory filing of another type. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2012-02-02 English
First Supplementary Target`s Statement By Hunter Immunology 6 pages 1.4MB
Merger & Acquisition Classification · 95% confidence The document is titled 'First Supplementary Target's Statement' and references the Corporations Act 2001 (Cth), ASIC lodgement, and a takeover offer by Probiomics Limited to acquire securities in Hunter Immunology Limited. It discusses proposed variations to an employment agreement, issuance of options contingent on takeover completion, and shareholder approval requirements under ASX Listing Rules and the Corporations Act. The content is focused on takeover bid details, supplementary disclosures to a prior Target's Statement, and conditions related to the acquisition and capital structure changes. This type of document is characteristic of takeover-related filings, specifically supplementary target's statements issued during a takeover bid process to update or clarify information for shareholders. Such documents fall under the category of Merger & Acquisition (MA) filings, which include takeover communications and related statements. The document is substantive and not merely an announcement or a proxy solicitation, and it is not a full annual or interim report, nor a regulatory filing or remuneration report. Therefore, the appropriate classification is Merger & Acquisition (MA).
2012-01-29 English
Appendix 4C - quarterly 5 pages 122.3KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, payments to directors, reconciliation of cash, and compliance statements. The report covers a quarter ended 31 December 2011, indicating it is a quarterly financial report. The content includes substantive financial data and analysis, not just an announcement or certification. The document length is 6945 characters, which is sufficient for a detailed quarterly report. The nature of the report aligns with an Interim / Quarterly Report (IR) as it provides comprehensive financial information for a period shorter than a full fiscal year. Q2 2011
2012-01-24 English
First Supplementary Bidder`s Statement for Hunter Immunology 9 pages 183.3KB
M&A Activity Classification · 95% confidence The document is titled 'First Supplementary Bidder’s Statement by Probiomics Limited' and references the Corporations Act 2001 (Cth), ASIC, and ASX, indicating it is an Australian regulatory filing related to a takeover bid. It supplements a prior Bidder’s Statement and discusses terms related to the acquisition of securities in Hunter Immunology Limited, including proposed variations to an employment agreement and issuance of options contingent on shareholder approval. The content is focused on takeover bid details, securities issuance, and shareholder meeting notices. This type of document is characteristic of merger and acquisition activity filings, specifically supplementary bidder statements which are part of the takeover process. It is not a full annual or interim report, earnings release, or other financial report. It is not a proxy solicitation or voting results announcement, but rather a detailed supplementary disclosure related to a takeover offer. Therefore, the appropriate classification is 'M&A Activity' (Code: TAR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2012-01-23 English
Notice of General Meeting/Proxy Form 78 pages 1.1MB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed information memorandum related to a General Meeting of shareholders, including a Notice of General Meeting, Proxy Forms, and explanatory materials. It discusses resolutions to be voted on at the meeting, including a takeover bid, capital raising, share consolidation, and a proposed company name change. The document is intended to inform shareholders and solicit their votes on these matters. It is not a financial report, earnings release, or audit report. It is not a simple announcement or regulatory filing but a comprehensive set of materials for a shareholder meeting. This fits the definition of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2012-01-05 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.